Patents Assigned to University of Connecticut Health Center
-
Patent number: 11934576Abstract: In accordance with one embodiment of the present disclosure, a method includes measuring brain activity for a target frequency and a second harmonic frequency based on a default value of display parameters for a plurality of icons, determining whether a strength of the target frequency and the second harmonic frequency are below a threshold level, and modifying one or more display parameters in response to the strength of the target frequency and the second harmonic frequency being below the threshold level.Type: GrantFiled: January 14, 2022Date of Patent: March 19, 2024Assignees: TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC., UNIVERSITY OF CONNECTICUT HEALTH CENTERInventors: Insoo Kim, Hossein Hamidi Shishavan, Kia Golzari, Muhamed Farooq, Ercan M. Dede
-
Publication number: 20230225654Abstract: In accordance with one embodiment of the present disclosure, a method includes generating a plurality of icons, wherein each icon has a target frequency unique from each other, receiving brain activity data based on an epoch, generating a reference signal based on the epoch, calculating correlation coefficients between the brain activity data and the reference signal, wherein the correlation coefficients are calculated in a window that is within ±0.5 Hz of the target frequencies, including endpoints, determining a confidence score based on the correlation coefficients and the epoch, and determining a selected icon among the plurality of icons based on the correlation coefficients in response to the confidence score surpassing a threshold confidence score.Type: ApplicationFiled: January 14, 2022Publication date: July 20, 2023Applicants: Toyota Motor Engineering & Manufacturing North America, Inc., University of Connecticut Health CenterInventors: Insoo Kim, Hossein Hamidi Shishavan, Kia Golzari, Muhamed Farooq
-
Publication number: 20230229235Abstract: In accordance with one embodiment of the present disclosure, a method includes measuring brain activity for a target frequency and a second harmonic frequency based on a default value of display parameters for a plurality of icons, determining whether a strength of the target frequency and the second harmonic frequency are below a threshold level, and modifying one or more display parameters in response to the strength of the target frequency and the second harmonic frequency being below the threshold level.Type: ApplicationFiled: January 14, 2022Publication date: July 20, 2023Applicants: Toyota Motor Engineering & Manufacturing North America, Inc., University of Connecticut Health CenterInventors: Insoo Kim, Hossein Hamidi Shishavan, Kia Golzari, Muhamed Farooq, Ercan M. Dede
-
Patent number: 11684301Abstract: In accordance with one embodiment of the present disclosure, a method includes generating a plurality of icons, wherein each icon has a target frequency unique from each other, receiving brain activity data based on an epoch, generating a reference signal based on the epoch, calculating correlation coefficients between the brain activity data and the reference signal, wherein the correlation coefficients are calculated in a window that is within ±0.5 Hz of the target frequencies, including endpoints, determining a confidence score based on the correlation coefficients and the epoch, and determining a selected icon among the plurality of icons based on the correlation coefficients in response to the confidence score surpassing a threshold confidence score.Type: GrantFiled: January 14, 2022Date of Patent: June 27, 2023Assignees: TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC., UNIVERSITY OF CONNECTICUT HEALTH CENTERInventors: Insoo Kim, Hossein Hamidi Shishavan, Kia Golzari, Muhamed Farooq
-
Publication number: 20170100455Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: ApplicationFiled: May 16, 2016Publication date: April 13, 2017Applicant: University of Connecticut Health CenterInventor: Pramod K. Srivastava
-
Patent number: 9566348Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.Type: GrantFiled: September 26, 2014Date of Patent: February 14, 2017Assignee: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Robert J. Binder
-
Patent number: 9352019Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: GrantFiled: April 27, 2015Date of Patent: May 31, 2016Assignee: University of Connecticut Health CenterInventor: Pramod K. Srivastava
-
Patent number: 9248172Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: GrantFiled: October 1, 2013Date of Patent: February 2, 2016Assignee: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Zihai Li
-
Publication number: 20150231200Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: ApplicationFiled: April 27, 2015Publication date: August 20, 2015Applicant: University of Connecticut Health CenterInventor: Pramod K. Srivastava
-
Publication number: 20150118253Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.Type: ApplicationFiled: September 26, 2014Publication date: April 30, 2015Applicant: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Robert J. Binder
-
Patent number: 8877204Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.Type: GrantFiled: February 20, 2004Date of Patent: November 4, 2014Assignee: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Robert J. Binder
-
Publication number: 20140107391Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: ApplicationFiled: October 1, 2013Publication date: April 17, 2014Applicant: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Zihai Li
-
Publication number: 20120021996Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: ApplicationFiled: September 30, 2011Publication date: January 26, 2012Applicant: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Zihai Li
-
Publication number: 20120021997Abstract: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an ?-2-macroglobulin (?2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an ?2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or ?2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.Type: ApplicationFiled: September 30, 2011Publication date: January 26, 2012Applicant: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Zihai Li
-
Patent number: 7666581Abstract: The present invention relates to methods and compositions for the prevention and treatment of infectious diseases, and cancers. The methods of the invention comprises complexing a population of antigenic proteins or antigenic peptides derived from antigenic cells or viral particles to one or more different heat shock proteins in vitro. The population or the protein preparation used to produce the antigenic peptides comprises at least 50% of the different proteins or at least 50 different proteins of the antigenic cells or viral particles. Methods for making antigenic peptides comprise digesting a protein preparation of antigenic cells, a cellular fraction thereof, or of viral particles with one or more proteases, or exposing the protein preparation to ATP, guanidium hydrochloride, and/or acidic conditions.Type: GrantFiled: August 20, 2002Date of Patent: February 23, 2010Assignee: University of Connecticut Health CenterInventor: Pramod K. Srivastava
-
Patent number: 7449557Abstract: The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.Type: GrantFiled: June 4, 2001Date of Patent: November 11, 2008Assignee: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Robert J. Binder
-
Patent number: 7186515Abstract: The present invention relates to the use of alpha (2) macroglobulin (“?2M”) receptor as a heat shock protein receptor, cells that express the ?2M receptor bound to an HSP, and antibodies and other molecules that bind the ?2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that modulate the interaction of an HSP with the ?2M receptor, and methods for using compositions comprising ?2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.Type: GrantFiled: July 25, 2000Date of Patent: March 6, 2007Assignee: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Robert J. Binder
-
Patent number: 7179462Abstract: The present invention relates to the use of alpha (2) macroglobulin (“?2M”) receptor as a heat shock protein receptor, cells that express the ?2M receptor bound to an HSP, and antibodies and other molecules that bind the ?2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that interact with the ?2M receptor, and modulate the interaction of the ?2M receptor with its ligand, such as HSPs, and methods for using compositions comprising ?2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.Type: GrantFiled: December 28, 2000Date of Patent: February 20, 2007Assignee: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Robert J. Binder
-
Publication number: 20070003555Abstract: The present invention relates to compositions and methods for the use of natural and recombinant p95 forms and fragments as heat shock protein binding proteins. The invention is based, in part, on the Applicant's discovery that a p95 can be recombinantly expressed. The present invention also relates to CD91 polypeptide fragments that comprise at least p95 and additional contiguous sequence from domain II, III, and IV of CD91.Type: ApplicationFiled: October 7, 2003Publication date: January 4, 2007Applicants: UNIVERSITY OF CONNECTICUT HEALTH CENTER, ANTIGENICS, INC.Inventor: Kenneth LeClair
-
Patent number: 7132109Abstract: The present invention provides for a method of using heat shock proteins (HSPs) to amplify the immune response initiated by a vaccine. HSPs can be introduced into a subject before, concurrently, or after the administration of a vaccine. The HSPs can also be used to activate antigen presenting cells which are then introduced into a subject in conjunction with a vaccine. The HSPs used in the methods of the invention can be unbound or can be covalently or noncovalently bound to a peptide that is unrelated to the vaccine. The subject is preferably mammalian, and most preferably human. It is shown by way of example herein that HSPs induces secretion of cytokines and surface expression of antigen-presenting and co-stimulatory molecules. The invention also encompasses methods of treatment and prevention of cancer and infectious diseases in a subject.Type: GrantFiled: October 20, 2000Date of Patent: November 7, 2006Assignee: University of Connecticut Health CenterInventor: Pramod K. Srivastava